Related references
Note: Only part of the references are listed.Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi
Carlo Visco et al.
LANCET HAEMATOLOGY (2017)
Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management
Julie M. Vose
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
Olivier Hermine et al.
LANCET (2016)
The use of formalin-fixed, paraffin-embedded lymph node samples for the detection of minimal residual disease in mantle cell lymphoma
Marketa Kalinova et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909
Hongtao Liu et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Treatment of Older Patients with Mantle-Cell Lymphoma
H. C. Kluin-Nelemans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study
Christiane Pott et al.
BLOOD (2010)
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
V. H. J. van der Velden et al.
LEUKEMIA (2007)
Share Paper
